Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBT (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed EBT for 11 consecutive years, with -$62.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 11.08% year-over-year to -$62.5 million, compared with a TTM value of -$155.2 million through Dec 2025, up 25.36%, and an annual FY2025 reading of -$155.2 million, up 25.36% over the prior year.
  • EBT was -$62.5 million for Q4 2025 at Spyre Therapeutics, down from -$11.2 million in the prior quarter.
  • Across five years, EBT topped out at -$6.7 million in Q2 2021 and bottomed at -$217.1 million in Q2 2023.
  • Average EBT over 5 years is -$42.6 million, with a median of -$30.6 million recorded in 2022.
  • The sharpest move saw EBT plummeted 872.82% in 2023, then skyrocketed 83.8% in 2025.
  • Year by year, EBT stood at -$20.4 million in 2021, then grew by 8.15% to -$18.8 million in 2022, then plummeted by 236.82% to -$63.2 million in 2023, then increased by 10.9% to -$56.3 million in 2024, then dropped by 11.08% to -$62.5 million in 2025.
  • Business Quant data shows EBT for SYRE at -$62.5 million in Q4 2025, -$11.2 million in Q3 2025, and -$36.7 million in Q2 2025.